Can Pfizer and Merck KGaA parlay Bavencio combo data into a kidney cancer win?

Pfizer and Merck's PD-L1 checkpoint inhibitor Bavencio previously won an FDA breakthrough designation for its Inlyta combo in kidney cancer. (Pfizer)

Pfizer and Merck KGaA are one step closer to a brand-new market for their immuno-oncology drug Bavencio. The companies reported winning data in a kidney cancer trial, setting them up for a "breakthrough" FDA approval—and a key expansion for the latecomer PD-L1 drug.

What's more, the potential nod puts Bavencio alongside Pfizer's Inlyta, a follow-up drug to its kidney cancer standard, Sutent. That means a new approval wouldn't just rev up Bavencio sales, but could drive Inlyta forward, too.

RELATED: The top 15 best-selling cancer drugs in 2022

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

In an interim analysis of the Javelin Renal study, the Bavencio-plus-Inlyta combo bettered Sutent alone at fending off kidney cancer's advance in previously untreated patients. And it wasn't just PD-L1 positive patients who showed a "statistically significant improvement" over Sutent monotherapy, but also patients who didn't test positive PD-L1 expression of 1% or more.

The partners plan to take the data to regulators to support their application for a new approval and are submitting the numbers for presentation at an upcoming medical meeting. The trial will go on to assess whether the combo can help patients live longer.

A new first-line combo approval would obviously be good news for Pfizer and Merck, particularly given Bavencio's fourth-to-market status in the PD-1/L1 market, behind Bristol-Myers Squibb's blockbuster Opdivo, Merck & Co.'s powerhouse Keytruda and Roche's Tecentriq. With Inlyta having flunked a trial aiming for a monotherapy expansion in patients after surgery, the combo approval will be especially important for Pfizer's hopes for both drugs.

RELATED: Bristol-Myers' Opdivo-Yervoy duo snares a quick FDA nod in first-line kidney cancer

But kidney cancer is heating up, and once again Bavencio is behind. Opdivo and fellow BMS drug Yervoy won a first-line combo approval in April, and Roche’s Tecentriq-plus-Avastin one-two punch put up its second phase 3 win back in February. A Keytruda-Inlyta phase 3 trial is currently ongoing, and Keytruda and Eisai's Lenvima—which Merck & Co. now shares—nabbed a breakthrough designation for first-line kidney cancer, too.

Suggested Articles

Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.

Roche’s Tecentriq scored some big wins lately, including a pair of first-in-class approvals. But in other cancers, it's decided to pull the plug.

Biosims haven't worked, experts say. Instead, it's time to for an independent body to set fair biologic prices after the drugs lose exclusivity.